Results 221 to 230 of about 94,635 (266)
Some of the next articles are maybe not open access.
Induction of Durable Remission in Ocular Inflammatory Diseases
European Journal of Ophthalmology, 2009Purpose To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission. Methods Retrospective cohort study.
C S Foster
exaly +3 more sources
The face of remission induction
British Journal of Haematology, 2019SummaryAcute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient‐related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little ...
Shilpa Paul +2 more
openaire +2 more sources
Natalizumab for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2006The pathogenesis of Crohn's disease involves migration of leukocytes into gut tissue and subsequent inflammation. Natalizumab (Tysabri(R), Elan Pharmaceuticals and Biogen Idec) a recombinant humanized IgG4 monoclonal antibody that blocks adhesion and subsequent migration of leukocytes into the gut by binding the alpha4 integrin is a member of a new ...
J K, Macdonald, J W D, McDonald
openaire +3 more sources
Budesonide for induction of remission in Crohn's disease
Cochrane Database of Systematic Reviews, 2015Corticosteroids are commonly used for the induction of remission in Crohn's disease. However, traditional corticosteroids can cause significant adverse events. Budesonide is an alternative glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission ...
Ali, Rezaie +7 more
openaire +2 more sources
Methotrexate for induction of remission in ulcerative colitis
2007Ulcerative colitis is a chronic inflammatory bowel disease. Corticosteroids and 5-aminosalicylates are the most commonly used therapies. However, many patients require immunosuppressive therapy when their disease becomes steroid-refractory or dependent.
N, Chande +2 more
openaire +2 more sources
INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICIN
The Lancet, 1978Doxorubicin (60 mg/m2 at 3-weekly intervals to a maximum total of 550 mg/m2) induced clinical remission in 14 (32%) of 44 patients with hepatocellular carcinoma. In 3 of those who responded, hepatic arteriography showed clearing of the previously extensive tumour circulation, and in a 4th there was disappearance of the tumour on serial ultrasound ...
P J, Johnson +4 more
openaire +2 more sources
Optimal induction and post-remission therapy for AML in first remission
Hematology, 2009AbstractApproximately 300,000 patients in the world are diagnosed annually with acute myeloid leukemia (AML). The median age at presentation has been steadily increasing over the past few decades and now is approaching 70 years. Although considerable progress has been made over the past 3 decades in the therapy of AML, two thirds of young adults still ...
openaire +2 more sources
Probiotics for induction of remission in ulcerative colitis
2006Ulcerative Colitis (UC) is an inflammatory condition affecting the colon with an incidence of approximately 10-20 per 100,000 per year. No existing intervention is effective in all patients with a proportion requiring colectomy. There are significant proportion of patients who experience adverse effects with current therapies.
P, Mallon +3 more
openaire +2 more sources
Budesonide for induction of remission in Crohn's disease
2008Corticosteroids play a key role in the induction of remission in Crohn's disease. However, corticosteroids can cause significant adverse events. Budesonide is an alternate enteral glucocorticoid with limited systemic bioavailability.The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn ...
Cynthia H, Seow +4 more
openaire +2 more sources
Budesonide for induction of remission in Crohn's disease
1996Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and ...
A, Otley, A H, Steinhart
openaire +2 more sources